Kisspeptin is the KISS1-gene neuropeptide that sits at the very top of the reproductive axis.

The short version

Kisspeptin is a small signalling molecule your body makes in the brain. Think of it as the master switch that turns the reproductive system on. When kisspeptin docks onto its receptor — KISS1R, an older name for it is GPR54 (a docking port on certain brain cells) — it tells those cells to release a hormone called GnRH (gonadotropin-releasing hormone). GnRH then tells the pituitary gland to release two more hormones, LH and FSH, which in turn drive the sex hormones. So kisspeptin sits at the top of that chain.

Researchers study kisspeptin for puberty, fertility, and IVF. It is investigational — no health agency has approved it for any use — and it is not a dietary supplement, despite being searched for as one. One quirk worth knowing: dose it continuously and the effect fades within days (called tachyphylaxis). What people actually report — including the downsides — is on the effects page.

What the Kisspeptin literature has established

Kisspeptin is the protein product of the KISS1 gene, and it is the principal upstream activator of GnRH neurons — the cells that pace the entire hypothalamic-pituitary-gonadal (HPG) axis ^[1]. The decisive evidence came in 2003: people carrying loss-of-function mutations in GPR54 (the kisspeptin receptor, now called KISS1R) failed to enter puberty and had low LH and FSH, and knockout mice reproduced the same phenotype, marking GPR54 as a gatekeeper of reproductive maturation ^[1].

The human research record is real but qualified. In healthy men, an intravenous kisspeptin-10 bolus of 1 ug/kg raised luteinizing hormone (LH — the pituitary hormone that drives testosterone and ovulation) from 4.1 to 12.4 IU/L within 30 minutes, and a higher continuous infusion raised testosterone from 16.6 to 24.0 nmol/L ^[3]. In women with hypothalamic amenorrhea (absent periods from a quieted reproductive axis), continuous kisspeptin-54 restored LH pulses roughly three-fold versus vehicle ^[4]. The headline clinical result is in IVF: a single subcutaneous kisspeptin-54 dose triggered egg maturation in 95% of women at high risk of ovarian hyperstimulation syndrome, with no case of moderate, severe or critical OHSS ^[5].

Doses throughout this site are reported only as what was administered to a stated population by a stated route — never as guidance. The kisspeptin mechanism of action page traces the cascade step by step, and the Kisspeptin research page logs each study.

Upstream of GnRH — what kisspeptin is, and is not

Kisspeptin acts upstream of GnRH: it drives your own GnRH neurons to fire. It is therefore distinct from GnRH itself and from GnRH-agonist drugs, and it is not a sex hormone — it does not supply LH, FSH, or testosterone, it triggers the body to make them ^[1]. Two research isoforms dominate the literature: kisspeptin-10 (the shorter, faster-clearing fragment) and kisspeptin-54 (the longer, longer-acting form originally named metastin) ^[3].

The "chemical" framing of this digest is deliberate: kisspeptin is studied as an investigational research peptide, not sold as a consumer product, so honest, sourced reading is the most useful thing a page can offer. The kisspeptin peptide primer covers the isoforms and the naming; the Kisspeptin effects page covers benefits, reported side effects, and who has reason for caution.

Why the discovery story matters

Kisspeptin was not found as a reproductive hormone at all. In 1996 the KISS1 gene was identified as a metastasis-suppressor in human melanoma — introducing it into metastatic melanoma cells suppressed their spread in mice — and the gene was named for Hershey, Pennsylvania, where it was discovered ^[8]. Its orphan receptor was deorphanized around 2001, and only in 2003 did the puberty link recast kisspeptin as the master switch of reproduction ^[1]. That arc — from cancer gene to reproductive gatekeeper — is why the literature spans oncology, endocrinology, and fertility, and why this digest reads it discovery-first.